3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮
| 中文名稱 | 3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 |
|---|---|
| 中文同義詞 | 3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮;化合物PKCΒ INHIBITOR 1;PKC尾 INHIBITOR;PKCΒ INHIBITOR 1 |CAS 257879-35-9;PKCβ抑制劑;3-(1-(3-咪唑-1-基丙基)-1H-吲哚-3-基)-4-苯胺-1H-吡咯-2,5-二酮 |
| 英文名稱 | PKCβ Inhibitor |
| 英文同義詞 | PKCβ Inhibitor;3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione;PKCβ inhibitor 1;KUN79359;1H-Pyrrole-2,5-dione, 3-[1-[3-(1H-imidazol-1-yl)propyl]-1H-indol-3-yl]-4-(phenylamino)-;PKCβ inhibitor 1,GSK3β,Inhibitor,tumor,PKCβ inhibitor1,proliferation,BCBL-1,mTOR,selective,inhibit,PKC,phosphorylation,cell,Apoptosis,PKCβ inhibitor-1,Protein kinase C,2F7,ATP-competitive;PKC2 inhibitor 1;3-(1-(3-(1H-Imidazol-1-yl)propyl)-1H-indol-3-yl)-4-(phenylamino)-1H-pyrrole-2,5-dione |
| CAS號 | 257879-35-9 |
| 分子式 | C24H21N5O2 |
| 分子量 | 411.46 |
| EINECS號 | |
| 相關(guān)類別 | 對照品 |
| Mol文件 | 257879-35-9.mol |
| 結(jié)構(gòu)式 | ![3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 結(jié)構(gòu)式](CAS/20180808/GIF/257879-35-9.gif) |
3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 性質(zhì)
| 溶解度 | DMF：10mg/mL； DMSO：10mg/mL；乙醇：1mg/mL； PBS（pH 7.2）：0.25 mg/mL |
|---|---|
| 形態(tài) | 固體 |
| 顏色 | 黃至橙色 |
|
human PKCβ1 21 nM (IC 50 ) |
human PKCβ2 5 nM (IC 50 ) |
PKCα 331 nM (IC 50 ) |
PKCβ inhibitor 1 (0-30 μM; 48 hours) suppresses tumor cell proliferation in a time- and dose-dependent manner.
PKCβ inhibitor 1 (14 μM; 2-48 hours) induces apoptosis in 2F7 cells.
PKCβ inhibitor 1 (15 μM; 2-48 hours) inhibits cell cycle progression in 2F7 and BCBL-1 cells.
PKCβ (15 or 14 μM, respectively; 2-48 hours) inhibitor 1 reduces the expression of phospho-PKCβ in BCBL-1 and 2F7 cells.
PKCβ inhibitor 1(0-48 hours) suppresses GSK3β, mTOR, and S6 phosphorylation.
Cell Proliferation Assay
| Cell Line: | 2F7, BCBL-1 cells |
| Concentration: | 0, 5, 10, 20, and 30 μM |
| Incubation Time: | 48 hours |
| Result: | A dose-dependent reduction in viability of the 2F7 and BCBL-1 cells starting at 5 μM and increasing with elevated inhibitor concentration. |
Apoptosis Analysis
| Cell Line: | 2F7 cells |
| Concentration: | 14 μM |
| Incubation Time: | 2-48 hours |
| Result: | Apoptotic induction in 2.1% of the 2F7 cells above background after 2 hours of treatment, increasing through 48 hours of treatment. |
Cell Cycle Analysis
| Cell Line: | BCBL-1 Cells |
| Concentration: | 15 μM (the IC 50 ) |
| Incubation Time: | 2-48 hours |
| Result: | Inhibits cell cycle progression in 2F7 and BCBL-1 cells. |
Western Blot Analysis
| Cell Line: | BCBL-1 and 2F7 cell lines |
| Concentration: | 15 or 14 μM (at the IC 50 respectively) |
| Incubation Time: | 2-48 hours |
| Result: | The expression of phospho-PKCβ in BCBL-1 and 2F7 cells reduced. |
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-13335 | 3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 PKCβ inhibitor 1 | 257879-35-9 | 500μg | 1100元 |
| 2026/06/05 | HY-13335 | 3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 PKCβ inhibitor 1 | 257879-35-9 | 1mg | 1800元 |